tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Saeki H | [Brief commentary on guidelines for the management of atopic dermatitis 2012 -the point of drug treatment]. | 2013 | Arerugi | pmid:24608647 |
| Ochiai T | [Advances in the fundamentals and therapeutic use of immunosuppressive agents]. | 1992 | Arerugi | pmid:1374229 |
| Teraki Y | [Atopic dermatitis in pregnancy]. | 2014 | Arerugi | pmid:24714179 |
| Ebihara N | [New strategy in the treatment of vernal keratoconjunctivitis by calcineurin inhibitor eye drops]. | 2010 | Arerugi | pmid:21119297 |
| Akutsu I et al. | [Inhibitory effects of cyclosporin A and FK-506 on eosinophil chemotactic factor activity in culture supernatants of mononuclear cells from asthmatics]. | 1992 | Arerugi | pmid:1280086 |
| Yamamoto S | [Guidelines for the management of atopic dermatitis 2006]. | 2008 | Arerugi | pmid:19052504 |
| Akutsu I et al. | [Inhibitory effect of inhaled FK-506 on increased bronchial responsiveness and eosinophil infiltration in the airway mucosa]. | 1992 | Arerugi | pmid:1377905 |
| Hossain M et al. | Effects of various drugs (staurosporine, herbimycin A, ketotifen, theophylline, FK506 and cyclosporin A) on eosinophil viability. | 1994 | Arerugi | pmid:7520689 |
| Akutsu I et al. | [Inhibitory effect of FK-506 on the development of late asthmatic response and on the increased bronchial responsiveness]. | 1990 | Arerugi | pmid:1705791 |
| Ohtsuki M | [Tacrolimus ointment for the treatment of atopic dermatitis]. | 2009 | Arerugi | pmid:19487830 |
| Nishimoto K et al. | [Case of organizing pneumonia associated with sweet's syndrome]. | 2014 | Arerugi | pmid:25163580 |
| Müller EG et al. | Tacrolimus eye drops as monotherapy for vernal keratoconjunctivitis: a randomized controlled trial. | 2017 | Arq Bras Oftalmol | pmid:28832739 |
| Liendo VL et al. | Topical tacrolimus for the treatment of severe allergic keratoconjunctivitis in children. | Arq Bras Oftalmol | pmid:28954018 | |
| Zulim LFDC et al. | Comparison of the efficacy of 0.03% tacrolimus eye drops diluted in olive oil and linseed oil for the treatment of keratoconjunctivitis sicca in dogs. | Arq Bras Oftalmol | pmid:29995121 | |
| Carvalho CS et al. | [Fibroblasts from recurrent pterygium and normal Tenon's capsule exposed to tacrolimus (FK-506)]. | 2007 Mar-Apr | Arq Bras Oftalmol | pmid:17589693 |
| Lasa J and Olivera P | EFFICACY OF TACROLIMUS FOR INDUCTION OF REMISSION IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS. | Arq Gastroenterol | pmid:28327826 | |
| Long C et al. | Removal of FKBP12/12.6 from endothelial ryanodine receptors leads to an intracellular calcium leak and endothelial dysfunction. | 2007 | Arterioscler. Thromb. Vasc. Biol. | pmid:17478757 |
| Ikezoe T et al. | Thrombomodulin protects endothelial cells from a calcineurin inhibitor-induced cytotoxicity by upregulation of extracellular signal-regulated kinase/myeloid leukemia cell-1 signaling. | 2012 | Arterioscler. Thromb. Vasc. Biol. | pmid:22796578 |
| Murakami R et al. | Cyclosporin A enhances interleukin-8 expression by inducing activator protein-1 in human aortic smooth muscle cells. | 2003 | Arterioscler. Thromb. Vasc. Biol. | pmid:12958044 |
| Vindis C et al. | Two distinct calcium-dependent mitochondrial pathways are involved in oxidized LDL-induced apoptosis. | 2005 | Arterioscler. Thromb. Vasc. Biol. | pmid:15618541 |
| Migita K et al. | Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus. | 2015 | Arthritis Res. Ther. | pmid:26036592 |
| Choe JY et al. | Regulatory effect of calcineurin inhibitor, tacrolimus, on IL-6/sIL-6R-mediated RANKL expression through JAK2-STAT3-SOCS3 signaling pathway in fibroblast-like synoviocytes. | 2013 | Arthritis Res. Ther. | pmid:23406906 |
| van der Windt AE et al. | Inhibiting calcineurin activity under physiologic tonicity elevates anabolic but suppresses catabolic chondrocyte markers. | 2012 | Arthritis Rheum. | pmid:22231955 |
| Suzuki N et al. | In vivo mechanisms for the inhibition of T lymphocyte activation by long-term therapy with tacrolimus (FK-506): experience in patients with Behçet's disease. | 1997 | Arthritis Rheum. | pmid:9182928 |
| de Paulis A et al. | Human synovial mast cells. II. Heterogeneity of the pharmacologic effects of antiinflammatory and immunosuppressive drugs. | 1997 | Arthritis Rheum. | pmid:9082935 |
| Cho ML et al. | Cyclosporine differentially regulates interleukin-10, interleukin-15, and tumor necrosis factor a production by rheumatoid synoviocytes. | 2002 | Arthritis Rheum. | pmid:11817607 |
| Kremer JM et al. | Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study. | 2003 | Arthritis Rheum. | pmid:14558080 |
| Asano Y et al. | Differential effects of the immunosuppressant FK-506 on human alpha2(I) collagen gene expression and transforming growth factor beta signaling in normal and scleroderma fibroblasts. | 2005 | Arthritis Rheum. | pmid:15818662 |
| Wilkes MR et al. | Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. | 2005 | Arthritis Rheum. | pmid:16052580 |
| Stone JH et al. | Outcome of renal transplantation in ninety-seven cyclosporine-era patients with systemic lupus erythematosus and matched controls. | 1998 | Arthritis Rheum. | pmid:9704643 |
| Yocum DE et al. | Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial. | 2003 | Arthritis Rheum. | pmid:14673984 |
| Furst DE et al. | Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. | 2002 | Arthritis Rheum. | pmid:12209503 |
| Cho ML et al. | Cyclosporine inhibition of vascular endothelial growth factor production in rheumatoid synovial fibroblasts. | 2002 | Arthritis Rheum. | pmid:12115224 |
| Parker CT and Rennie T | Failure to report previously used drugs and dosages in pharmaceutical company-sponsored rheumatoid arthritis trials: comment on the article by Yocum et al. | 2004 | Arthritis Rheum. | pmid:15457479 |
| Haisheng H et al. | Assessment of nerve regeneration across nerve allografts treated with tacrolimus. | 2008 | Artif Cells Blood Substit Immobil Biotechnol | pmid:18925465 |
| Dawson S et al. | UCLA liver transplantation: analysis of immunological factors affecting outcome. | 1996 | Artif Organs | pmid:8896726 |
| Kashu Y et al. | Prolongation of rat liver graft survival by splenectomy combined with low dose FK506 therapy. | 1996 | Artif Organs | pmid:8896731 |
| Ohshima S et al. | Immunosuppressive treatment of primary cadaveric renal transplant patients receiving kidneys from non-heart beating donors. | 1996 | Artif Organs | pmid:8896734 |
| Wada Y et al. | BCX-34: a novel T-cell selective immunosuppressant: purine nucleoside phosphorylase (PNP) inhibitor. | 1996 | Artif Organs | pmid:8853794 |
| Imanishi Y et al. | Pharmacokinetic properties of a once-daily formulation of tacrolimus in patients with renal transplantation. | 2011 | Arzneimittelforschung | pmid:21528645 |
| Takayama T et al. | Effects of the novel and potent lymphocyte-specific protein tyrosine kinase inhibitor TKM0150 on mixed lymphocyte reaction and contact hypersensitivity in mice. | 2010 | Arzneimittelforschung | pmid:20533766 |
| Lainesse A et al. | Bioequivalence studies of tacrolimus capsule under fasting and fed conditions in healthy male and female subjects. | 2008 | Arzneimittelforschung | pmid:18589558 |
| Haehner T et al. | Drug-drug interactions evaluated by a highly active reconstituted native human cytochrome P4503A4 and human NADPH-cytochrome P450 reductase system. | 2004 | Arzneimittelforschung | pmid:14979613 |
| MarcelÃn-Jiménez G et al. | Development of an ultra-performance liquid chromatography technique coupled with mass spectrometry for the measurement of tacrolimus in micro-samples of whole blood, and its application on a pharmacokiinetic trial. | 2007 | Arzneimittelforschung | pmid:18074760 |
| Iwasaki K et al. | Effect of repeated oral doses of a novel immunosuppressive macrolide lactone on hepatic mixed-function oxidase system in the rat. Comparative study with ciclosporin. | 1992 | Arzneimittelforschung | pmid:1379812 |
| Cacciarelli TV et al. | Influence of the timing of FK 506 (Tacrolimus) administration on recovery of renal function from warm ischemic injury in rats. | 1994 Oct-Dec | ASAIO J. | pmid:7532042 |
| Tsubo T et al. | Elimination of FK-506 by continuous hemodiafiltration in a liver transplant patient. | 1997 Jul-Aug | ASAIO J. | pmid:9242954 |
| Ogita K et al. | Renal tubular acidosis secondary to FK506 in living donor liver transplantation: a case report. | 2003 | Asian J Surg | pmid:14530108 |
| Li T et al. | Effect of FK506 nanospheres on regeneration of allogeneic nerve after transplant. | 2014 | Asian Pac J Trop Med | pmid:25066398 |
| Dai YJ et al. | Effect of pharmacological intervention on MIP-1α, MIP-1β and MCP-1 expression in patients with psoriasis vulgaris. | 2014 | Asian Pac J Trop Med | pmid:25063291 |
| Yasukochi Y et al. | Reduction of serum TARC levels in atopic dermatitis by topical anti-inflammatory treatments. | 2014 | Asian Pac. J. Allergy Immunol. | pmid:25268342 |
| Labcharoenwongs P et al. | A double-masked comparison of 0.1% tacrolimus ointment and 2% cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children. | 2012 | Asian Pac. J. Allergy Immunol. | pmid:23156846 |
| Manuyakorn W et al. | In vitro cytokine changes after pediatric liver transplantation. | 2015 | Asian Pac. J. Allergy Immunol. | pmid:25840634 |
| Clark K et al. | Oxidative Stress Induces Disruption of the Axon Initial Segment. | ASN Neuro | pmid:29228786 | |
| Riba Torrecillas D et al. | [Use of topical tacrolimus and its side-effects]. | 2005 | Aten Primaria | pmid:15946616 |
| Ichimaru N et al. | Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. | 2001 | Atherosclerosis | pmid:11583721 |
| Hamada N et al. | Tacrolimus-eluting stent inhibits neointimal hyperplasia via calcineurin/NFAT signaling in porcine coronary artery model. | 2010 | Atherosclerosis | pmid:19682688 |
| Matsumoto T et al. | Influence of FK506 on experimental atherosclerosis in cholesterol-fed rabbits. | 1998 | Atherosclerosis | pmid:9699896 |
| Grillo E et al. | Necrobiosis lipoidica. | 2014 | Aust Fam Physician | pmid:24600675 |
| Grillo E et al. | Skin rash associated with limb weakness. | 2012 | Aust Fam Physician | pmid:23210105 |
| Cooley HM et al. | Resolution of pyoderma gangrenosum using tacolimus (FK-506) | 1996 | Aust N Z J Med | pmid:8744629 |
| Chung TH et al. | Topical tacrolimus (FK506) for the treatment of feline idiopathic facial dermatitis. | 2009 | Aust. Vet. J. | pmid:19796164 |
| Dall'Olio E et al. | Erosive pustular dermatosis of the leg: long-term control with topical tacrolimus. | 2011 | Australas. J. Dermatol. | pmid:21332681 |
| Shamsudin N et al. | Objective assessment of vitiligo with a computerised digital imaging analysis system. | 2015 | Australas. J. Dermatol. | pmid:25367709 |
| Dar NR and Rao SU | Facial lichen nitidus actinicus. | 2012 | Australas. J. Dermatol. | pmid:22571575 |
| Milcic D and Nikolic M | Clinical effects of topical pimecrolimus in a patient with Fox-Fordyce disease. | 2012 | Australas. J. Dermatol. | pmid:22571582 |
| Lee FJ et al. | Poor efficacy of oral tacrolimus in the treatment of severe generalized atopic eczema in adults: a small retrospective case series. | 2012 | Australas. J. Dermatol. | pmid:23157781 |
| Zirbs M et al. | Demodicidosis associated with psoriasis therapy--two case reports. | 2013 | Australas. J. Dermatol. | pmid:23905976 |
| Patterson C and Coutts I | Granuloma faciale successfully treated with topical tacrolimus. | 2009 | Australas. J. Dermatol. | pmid:19659988 |
| Cassis TB and Callen JP | Bupropion-induced subacute cutaneous lupus erythematosus. | 2005 | Australas. J. Dermatol. | pmid:16197429 |
| Wilson LM and Reid CM | Molluscum contagiosum in atopic dermatitis treated with 0.1% tacrolimus ointment. | 2004 | Australas. J. Dermatol. | pmid:15250900 |
| Christophers E | Psoriasis: mechanisms and entry points for possible therapeutic interventions. | 1996 | Australas. J. Dermatol. | pmid:8713012 |
| Pirmez R et al. | Acne keloidalis nuchae in renal transplant patients receiving tacrolimus and sirolimus. | 2016 | Australas. J. Dermatol. | pmid:27124649 |
| Starritt E and Lee S | Erythroplasia of Queyrat of the glans penis on a background of Zoon's plasma cell balanitis. | 2008 | Australas. J. Dermatol. | pmid:18412812 |
| Black M and Marshman G | Dermatomyositis and pemphigus vulgaris: association or coincidence? | 2011 | Australas. J. Dermatol. | pmid:21605086 |
| Hannah J et al. | Tacrolimus use in lupus nephritis: A systematic review and meta-analysis. | 2016 | Autoimmun Rev | pmid:26427983 |
| Shinkura N et al. | Autoantibodies to FK506 binding protein 12 (FKBP12) in autoimmune diseases. | 1999 | Autoimmunity | pmid:10433096 |
| Maalej A et al. | Evidence of association between FKBP1B and thyroid autoimmune disorders in a large Tunisian family. | 2004 | Autoimmunity | pmid:15497458 |
| Thomson AW et al. | ICAM-1 and E-selectin expression in lesional biopsies of psoriasis patients responding to systemic FK 506 therapy. | 1993 | Autoimmunity | pmid:7505632 |
| Lemster B et al. | Influence of FK 506 (tacrolimus) on circulating CD4+ T cells expressing CD25 and CD45RA antigens in 19 patients with chronic progressive multiple sclerosis participating in an open label drug safety trial. | 1994 | Autoimmunity | pmid:7539635 |
| Thomson AW and Starzl TE | FK 506 and autoimmune disease: perspective and prospects. | 1992 | Autoimmunity | pmid:1382646 |
| Mochizuki M and Kawashima H | Effects of FK506, 15-deoxyspergualin, and cyclosporine on experimental autoimmune uveoretinitis in the rat. | 1990 | Autoimmunity | pmid:1717007 |
| Ni M et al. | FR900506 (FK506) and 15-deoxyspergualin (15-DSG) modulate the kinetics of infiltrating cells in eyes with experimental autoimmune uveoretinitis. | 1990 | Autoimmunity | pmid:1717008 |
| Matsumura C et al. | Differential effects of FK506 and cyclosporin A on catecholamine release from bovine adrenal chromaffin cells. | 2004 | Auton Autacoid Pharmacol | pmid:15541012 |
| Nakagaki T et al. | FK506 reduces abnormal prion protein through the activation of autolysosomal degradation and prolongs survival in prion-infected mice. | 2013 | Autophagy | pmid:23800841 |
| Gates T | Atopic dermatitis: diagnosis, treatment, and aeromedical implications. | 2007 | Aviat Space Environ Med | pmid:17225479 |
| Ekici Günay N et al. | Administration of Extract (EGb761) Alone and in Combination with FK506 Promotes Liver Regeneration in a Rat Model of Partial Hepatectomy. | 2018 | Balkan Med J | pmid:29553465 |
| Kise H et al. | Cardiac and haemodynamic effects of tacrolimus in the halothane-anaesthetized dog. | 2010 | Basic Clin. Pharmacol. Toxicol. | pmid:19912168 |
| Zhang H et al. | Prediction of Drug-Drug Interaction between Tacrolimus and Principal Ingredients of Wuzhi Capsule in Chinese Healthy Volunteers Using Physiologically-Based Pharmacokinetic Modelling. | 2018 | Basic Clin. Pharmacol. Toxicol. | pmid:28945011 |
| Han N et al. | Population pharmacokinetic-pharmacogenetic model of tacrolimus in the early period after kidney transplantation. | 2014 | Basic Clin. Pharmacol. Toxicol. | pmid:24238261 |
| Huang F et al. | Pharmacokinetic Interaction between Faldaprevir and Cyclosporine or Tacrolimus in Healthy Volunteers: A Prospective, Open-Label, Fixed-Sequence, Crossover Study. | 2018 | Basic Clin. Pharmacol. Toxicol. | pmid:29427400 |
| Quteineh L et al. | Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. | 2008 | Basic Clin. Pharmacol. Toxicol. | pmid:19067682 |
| Kagaya H et al. | Correlation of IMPDH1 gene polymorphisms with subclinical acute rejection and mycophenolic acid exposure parameters on day 28 after renal transplantation. | 2010 | Basic Clin. Pharmacol. Toxicol. | pmid:20136638 |
| Kim IW et al. | Identification of factors affecting tacrolimus level and 5-year clinical outcome in kidney transplant patients. | 2012 | Basic Clin. Pharmacol. Toxicol. | pmid:22469198 |
| Panahi Y et al. | Comparison of clinical efficacy of topical pimecrolimus with betamethasone in chronic skin lesions due to sulfur mustard exposure: a randomized, investigator-blind study. | 2009 | Basic Clin. Pharmacol. Toxicol. | pmid:19143752 |
| Velickovic-Radovanovic RM et al. | Clinical pharmacokinetics of tacrolimus after the first oral administration in renal transplant recipients on triple immunosuppressive therapy. | 2010 | Basic Clin. Pharmacol. Toxicol. | pmid:20102364 |
| Hisamura F et al. | Protective effect of green tea extract and tea polyphenols against FK506-induced cytotoxicity in renal cells. | 2006 | Basic Clin. Pharmacol. Toxicol. | pmid:16445594 |
| Hu R et al. | CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation. | 2018 | Basic Clin. Pharmacol. Toxicol. | pmid:29603629 |
| Cumming DV et al. | Pharmacological preconditioning of primary rat cardiac myocytes by FK506. | 1996 Sep-Oct | Basic Res. Cardiol. | pmid:8922254 |
| Ikeda Y et al. | Activation of ERK and suppression of calcineurin are interacting mechanisms of cardioprotection afforded by delta-opioid receptor activation. | 2006 | Basic Res. Cardiol. | pmid:16619106 |